Tech Company Financing Transactions
Kenai Therapeutics Funding Round
Kenai Therapeutics secured a $82 million Series A investment round on 2/29/2024. Investors included Alaska Permanent Fund, The Column Group and Euclidean Capital.
Transaction Overview
Company Name
Announced On
2/29/2024
Transaction Type
Venture Equity
Amount
$82,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to submit an IND for RNDP-001 and complete Phase 1 clinical trials, which will initiate within the year.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
One Broadway 14th Floor Kendall Square
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
We are advancing off-the-shelf dopamine neuron replacement therapies as a disease-modifying and potentially curative treatment for neurological disorders. Our proprietary platform leverages a novel approach to treating central nervous system disorders, such as Parkinson's disease, by replacing neurons lost due to neurodegeneration.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nicholas Manusos
Chief Financial Officer
Rajesh Mistry
Chief Medical Officer
Howard Federoff
VP - General Counsel
Martin Ostrowski
Browse more venture capital transactions:
Prev: 2/29/2024: Heat Geek venture capital transaction
Next: 3/1/2024: Sitehop venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to record every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs